Press Releases May 5, 2026 07:30 AM

Intellia Therapeutics to Participate in Upcoming Investor Conferences

Intellia Therapeutics announces participation in multiple upcoming investor conferences to discuss company progress and strategy.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
NTLA

Intellia Therapeutics, a clinical-stage biopharmaceutical company focused on CRISPR gene editing, will participate in investor fireside chats at three major healthcare conferences in May and June 2026. The events will be webcast live, offering investors insights into the company's mission to develop potentially curative treatments targeting the root causes of severe diseases.

Intellia Therapeutics to Participate in Upcoming Investor Conferences
NTLA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Intellia will engage with investors at Bank of America, RBC Capital Markets, and Jefferies Global Healthcare Conferences.
  • The sessions will provide updates on Intellia's advancements in CRISPR gene editing technologies and clinical progress.
  • Participation aims to enhance investor relations and transparency via live webcasts and replays.

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that management will be participating in fireside chats at the following upcoming investor conferences:

  • Bank of America Securities Health Care Conference
    Date: Tuesday, May 12, 2026
    Fireside Chat Time: 3:40 p.m. PT
    Location: Las Vegas
  • RBC Capital Markets Global Healthcare Conference
    Date: Wednesday, May 20, 2026
    Fireside Chat Time: 2:35 p.m. ET
    Location: New York
  • Jefferies Global Healthcare Conference
    Date: Wednesday, June 3, 2026
    Fireside Chat Time: 4:55 p.m. ET
    Location: New York

The fireside chats will be webcast live. To join the webcasts, please visit the Events and Presentations page of the Investors & Media section on Intellia’s website at intelliatx.com. Replays of the webcasts will be available on the same page for approximately 90 days following the events.

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicommunications.com 


Risks

  • As a clinical-stage biotech company, Intellia faces the inherent risk of clinical trial outcomes and regulatory approvals affecting future prospects.
  • The biopharmaceutical sector is highly competitive, with rapid technological advancements potentially impacting Intellia's market position.
  • Market and investor sentiment can be volatile in the biotech field, potentially influencing stock price independent of current news.

More from Press Releases

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress Jun 14, 2026 Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Jun 14, 2026 Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026